Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC2A1 | P11166 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 2/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.32 |
| ▸ | PDE4A | P27815 | 4/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21191549 | 0.85 | PDE4A (0.34) | GAATSHRPDE4A | |
| SCHEMBL22023873 | 0.82 | PDE4A (0.33) | GAATSHRPDE4A | |
| SCHEMBL22024008 | 0.79 | CCR2 (0.36) | PDE4AALDH1A1 | |
| SCHEMBL23634129 | 0.79 | CCR2 (0.36) | PDE4AALDH1A1 | |
| SCHEMBL14592897 | 0.79 | ALDH1A1 (0.34) | GAATSHRCRBNPDE4AALDH1A1 | |
| SCHEMBL14592820 | 0.79 | ALDH1A1 (0.34) | GAATSHRCRBNPDE4AALDH1A1 | |
| SCHEMBL8931418 | 0.79 | ALDH1A1 (0.34) | GAATSHRCRBNPDE4AALDH1A1 | |
| SCHEMBL22023926 | 0.78 | PDE4A (0.35) | GAATSHRPDE4AALDH1A1 | |
| SCHEMBL3973887 | 0.77 | CCR2 (0.35) | TSHRPDE4A | |
| SCHEMBL21884191 | 0.77 | CCR2 (0.34) | PDE4AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230226196-A1 | COMPOUNDS FOR TARGETED DEGRADATION OF INTERLEUKIN-2-INDUCIBLE T-CELL KINASE AND METHODS OF USE | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2023-07-20 | — | — | US | disclosed |
| US-20220401564-A1 | SELECTIVE HISTONE DEACETYLASE (HDAC) DEGRADERS AND METHODS OF USE THEREOF | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2022-12-22 | — | — | US | disclosed |
| US-11198693-B2 | Functionalized heterocycles as antiviral agents | ENANTA PHARMACEUTICALS, INC. (US) | 2021-12-14 | — | — | US | disclosed |
| WO-2020108538-A1 | RORγ INHIBITOR HAVING SULFONYL STRUCTURE | 正大天晴药业集团股份有限公司 | 2020-06-04 | — | — | WO | disclosed |
| US-20200165249-A1 | FUNCTIONALIZED HETEROCYCLES AS ANTIVIRAL AGENTS | ENANTA PHARMACEUTICALS, INC. | 2020-05-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230226196-A1 | COMPOUNDS FOR TARGETED DEGRADATION OF INTERLEUKIN-2-INDUCIBLE T-CELL KINASE AND METHODS OF USE | ITK, IKZF2, PBK | SLC2A1 4353/4885GAA 1040/4885TSHR 2992/4885 |
| US-20220401564-A1 | SELECTIVE HISTONE DEACETYLASE (HDAC) DEGRADERS AND METHODS OF USE THEREOF | HDAC3, HDAC1, HDAC2 | SLC2A1 3609/4885GAA 68/4885TSHR 3076/4885 |
| US-11198693-B2 | Functionalized heterocycles as antiviral agents | HCCS, HAVCR2, HDGF | SLC2A1 3821/4885GAA 937/4885TSHR 3380/4885 |
| US-20200165249-A1 | FUNCTIONALIZED HETEROCYCLES AS ANTIVIRAL AGENTS | HCCS, HAVCR2, HDGF | SLC2A1 3821/4885GAA 937/4885TSHR 3380/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.